Adoptracell, INC.

AdopTracell, INC. is a preclinical-stage biotechnology company focused on the development of next-generation autoimmune therapies. The company specializes in the engineering of regulatory T cells (Tregs), utilizing chimeric antigen receptor (CAR) technology to improve immune tolerance. Their primary research efforts target Type 1 Diabetes (T1D) by developing GAD65-targeting CAR-Tregs designed to home to pancreatic islets, suppress diabetogenic T cells, and promote beta-cell recovery. The organization is led by a team of academic physicians and scientists with expertise in gene and cell therapy.

The company's work aims to address limitations in current Treg therapies, such as the low availability of antigen-specific cells, by creating targeted interventions that provide effective immune suppression without the adverse effects associated with broader immunotherapies. Preclinical studies have indicated that their GAD65-CAR-Treg approach can improve blood glucose levels and insulin concentrations while maintaining a favorable safety profile. AdopTracell’s development is supported by academic and state-level grants, reflecting its mission to transition fundamental research into clinical applications for autoimmune conditions.